Intrexon sets IPO range

Synthetic biology company Intrexon Corp. (Germantown, Md.) amended its IPO and now plans to sell 8.3 million shares at $14-$16. At the $15 midpoint, the company would raise $125 million and be valued at $374.2 million. According to the SEC filing, Intrexon Chairman and CEO Randal Kirk and affiliates have indicated an interest to purchase up to $30 million worth of shares in the offering, which is being underwritten by JPMorgan; Barclays; Griffin Securities; and Mizuho. ...